Rocala2811

Oncóloga Médica y Uro-Oncóloga, comprometida con los pacientes y el aprendizaje continuo

[gilberto lopes @GlopesMd]

@asco #asco26 is four weeks away. Looking forward to seeing everyone in Chicago.

Eagerly awaited: Plenary Session trials

PROTEUS - Perioperative apalutamide + ADT vs placebo + ADT with radical prostatectomy in high-risk localized / locally advanced prostate cancer

SARC041 - Abemaciclib vs placebo in advanced dedifferentiated liposarcoma

LIBRETTO-432 - Adjuvant selpercatinib vs placebo in stage IB–IIIA RET fusion–positive NSCLC

HARMONi-6 - Ivonescimab + chemotherapy vs tislelizumab + chemotherapy in previously untreated advanced squamous NSCLC (overall survival results)

RASolute 302 - Daraxonrasib (RAS(ON) multi-selective inhibitor) vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma

@OncoAlert @OncBrothers @uicc @IASLC @COlazagasti @Latinamd @Jani_Chinmay @JackWestMD

[Aakash Desai @ADesaiMD]

🚨 FDA approval update in #EGFRm NSCLC @EGFRSummit

@US_FDA approves Rybrevant® FASPRO (amivantamab + hyaluronidase) ➕ lazertinib for 1L EGFR-mutant NSCLC.

◻️SC administration
◻️ Shorter, simpler dosing
◻️ Meaningful step forward for clinic workflow & patient experience

Delivery matters—this is progress! Also excited for the reduced #timetoxicity on patients!
@LungCancerRx @OncBrothers @OncoAlert @oncodaily

[Stephen V Liu, MD @StephenVLiu]

Dr. @APassaroMD discusses #EGFR NSCLC at the @LungSummit. Combination therapy should now be considered our standard for first-line therapy with OS advantages seen using osi + chemo (FLAURA2) and amivantamab + lazertinib (MARIPOSA). Learning about impact on acquired resistance.

[Mónica Saade @MonicaSaadeX]

Con la izquierda NO, es con la DERECHA…. ❤️🇨🇴

[Dr Rishabh Jain @DrRishabhOnco]

⏩ From PFS to OS: MARIPOSA confirms Amivantamab–Lazertinib improves survival in EGFR+ NSCLC 🫁🌟

📖 Phase 3 | EGFR Ex19del/L858R | First-line advanced NSCLC

🔹 Trial Arms
• 🧪 Amivantamab + Lazertinib (n=429)
• 💊 Osimertinib (n=429)

📊 Overall Survival (FU 37.8 mo)
🕰️ HR 0.75 (95% CI 0.61–0.92, p=0.005)
🎯 3-yr OS: 60% v/s 51%
📈 Median OS: NE v/s 36.7 mo
🔄 Still on Tx: 38% v/s 28%

⏳ Other Endpoints
🩺 Symptomatic PFS: 43.6 v/s 29.3 mo (HR 0.69)
🧠 Intracranial PFS: 25.4 v/s 22.2 mo (HR 0.79)

🛡️ Safety Profile
⚠️ Gr ≥3 AEs: 80% v/s 52%
🩹 Rash, 💉 infusion reactions, 🫀 VTE ↑
✅ No new safety signals

✨ Takeaway
Amivantamab–Lazertinib = first chemo-free combo showing OS benefit over Osimertinib in frontline EGFR+ NSCLC 🚀

📖 Yang JCH et al. N Engl J Med 2025.
DOI: https://t.co/sQ069QtXuC

#OncoTwitter #MedTwitter #LungCancer #TargetedTherapy
@OncoAlert @myesmo @esmo_open @asco @NEJM

[Oncology Brothers @OncBrothers]

~1 week to #ESMO24, here is a📝 of 🔑abstracts for general onc that could change/reinforce our SoC!

- #NIAGARA
- #KN522
- #NATALEE
- #DB12
- #MARIPOSA2
- #KRYSTAL12
- #NICHE2
- #SAKK41
- #POD1UM
- #KN811

#BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter @myESMO @OncoAlert

[Rocala2811 @relc_uroonco]

5 meses de #GlowUp laboral. Crecimiento, trabajo en equipo, valor por tu trabajo, resiliencia, compromiso, reconocimiento, ética y muchas cosas más que hacen que tu trabajo sea tu happy place es lo q significa ser MM del team pulmón. Por muchos meses más !!!

[Maite Bourlon @BourlonMaite]

Just at #gu2024 @ASCO
🔹Keynote 564! Adjuvant pembrolizumab in resected high risk RCC has OS benefit! @DrChoueiri

🔸@PBarataMD discussed the data & highlighted our ASCO Daily News of What to do in patients recurring after adjuvant pembrolizumab?

https://t.co/UxLLI8Mu5r

[Maite Bourlon @BourlonMaite]

Great! “PARPi for prostate cancer”
🔹1st targeted therapy for advanced disease
✅ TRITON-3 & PROFOUND showed benefit in mCRPC w DDR alt
‼️PROPEL, TALAPRO-2 & MAGNITUDE in 1L mCRPC but mostly unexposed to ARSi
Is PARPi rechallenge possible?
@Ecastromarcos @PaolaVS94 👩🏻‍⚕️🇲🇽🇪🇸

[Yuly A. Remolina @Yuly_Remo]

Impact of healthcare inequities on survival in Mexican patients with metastatic renal cell carcinoma https://t.co/fYWO9ldVmg

[Sumanta K. Pal, MD, FASCO @montypal]

Eloquent discussion from @apolo_andrea @theNCI synthesizing data from #EV302 & #CM901. Loved the fact that she offered a strong, definitive opinion on the "winner" in the battle between these options. Also (not shown) great outline of remaining questions - what comes after EVP? #ESMO23

[Maite Bourlon @BourlonMaite]

📢 BMS @bmsnews Press release on CheckMate-67T study of subcutaneous Nivolumab while @myESMO begins

🔹P3 trial of SC Nivo vs IV Nivo
🔸Meets co-primary endpoints of Pharmacokinetics 👩🏻‍🔬
🔹Meets non-inferiority in ORR (secondary endpoint)

Great team @AlbigesL @INCMNSZ_Uronco

[Diego Barreiro @DBarreiro4]

Si removemos el tacto rectal de las guías…

Mayor cantidad de hombres realizará chequeos?

Al fin podremos disminuir el 40% de cancer de prostata metastasico de novo en LATAM ?

El machismo aleja a los hombres del diagnóstico precoz?

Espero sus puntos de vista…

[Maite Bourlon @BourlonMaite]

Happy collaborator: WOMEN, POWER & CANCER @TheLancet Commission

Lead by @OphiraG & great team @NarjustFlorezMD @dmukherji @EnriqueSoto8

🔸Cancer one of top 3 causes of premature death 🌍
🔹Gender transformative policies needed👩🏻‍⚕️
🔸Risk fx: Tobacco alcohol obesity & infections

[Enrique Grande @drenriquegrande]

EV302 IS POSITIVE!!!!!!! 🥂🍾Amazing news for Urothelial Cancer field!!!! Congratulations to my friend @tompowles1 and the rest of the team!!!!! @OncoAlert @GuardConsortium
Merck Announces Phase 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer https://t.co/dztSsOgtFf

[Maite Bourlon @BourlonMaite]

The therapeutic landacape of #bladdercancer has changed!!

✅ Patients w FGFR alterations can be treated w erdafitinib 👩🏻‍🔬🏨🧬

🔹Phosphorus needed for dose titration 🫙
🔹Skin, nails & 👁️ toxicity!!!
🔹High disease control rate

@EvelynBeas2 @Yuly_Remo @DrFrancas @TomFlaigMD

[Maite Bourlon @BourlonMaite]

A Potpourri of options in 1L metastatic urothelial carcinoma. Are we ready to select???

Thanks @ASCO for inviting me 👩🏻‍⚕️🇲🇽🏨! @ConquerCancerFd @OncoAlert

Thanks to the supportive GU cancers community @apolo_andrea @TomFlaigMD @DrChoueiri @montypal @tompowles1 @Ecastromarcos

[Roy Herbst @DrRoyHerbst]

Thank you to @ConquerCancerFd for all you do to support young investigators @ASCO I myself was a recipient of both a YIA and CDA award and know personally how important these are for one’s career. What an inspiring event tonight in Chicago @ASCOPres @tarasanftmd @PamelaKunzMD

[Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ @APassaroMD]

#ASCO23 🔥@ASCO

[Rocala2811 @relc_uroonco]

Thank you @ConquerCancerFd for this opportunity to learn and assist yo @ASCO, thanks to my mentor @BourlonMaite, who has supported and taught that you must work hard for you dreams.
#IDEA2023 awards